Provided are a long-acting prodrug of Rasagiline, which has application in the treatment of Central Nervous System diseases such as Parkinson's disease, preparation method and use thereof. The long-acting prodrug of Rasagiline has a structure of formula (I), wherein T is absent, or T is selected fromeach of R1 and R2 is independently selected from H, D, and alkyl; W is absent, or W is selected from (CH2)n, wherein n is an integer selected from 1 to 15; X is absent, or X is selected from (CH2)m, wherein m is an integer selected from 1 to 10; Y is absent, or Y is selected from —;C(═;O)NH—;, —;NHC(═;O)—;; R3 is selected from substituted or unsubstituted C1-C30 alkyl, substituted or unsubstituted C2-C30 alkenyl, substituted or unsubstituted C2-C30 alkynyl, substituted or unsubstituted C3-C30 cycloalkyl, cholane aliphatic group, —;R3a—;C(═;O)O—;R3b, —;R3a—;OC(═;O)—;R3b, —;R3a—;C(═;O)NH—;R3b, —;R3a—;NHC(═;O)—;R3b, —;R3a—;S(═;O)1-2O—;R3b and —;R3a—;OS(═;O)1-2—;R3b.